DETROIT, Aug. 11 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. has launched sumatriptan succinate tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma), immediately following Sun Pharma’s recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Imitrex(R) tablets. These sumatriptan succinate tablets, 25 mg (base), 50 mg (base) and 100 mg (base) are therapeutically equivalent to Imitrex(R) tablets from GlaxoSmithKline. Sumatriptan succinate tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.
Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation’s largest wholesalers, distributors, drugstore chains and managed care providers.
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
CONTACT: Jitendra Doshi, +1-313-556-4104, or Thomas Versosky,
+1-313-556-4150, both of Caraco Pharmaceutical
